Carotid Stenotic Scan Devices Market By Product (Carotid Duplex and Color Doppler Ultrasound Systems, Computed Tomography Angiography Systems, Magnetic Resonance Angiography Systems, Digital-Subtraction and Catheter Angiography Systems); By Application (Initial Detection and Stenosis Grading, Stroke and Transient Ischemic Attack Work-Up, Preoperative and Pre-Stenting Assessment, Disease Progression Monitoring, Post-Revascularization Surveillance); By End User (Hospitals and Stroke Centers, Vascular Laboratories, Diagnostic Imaging Centers, Vascular Surgery and Specialist Clinics, Ambulatory and Interventional Centers, Academic and Research Institutions); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Carotid Stenotic Scan Devices Market: Market Scope and Strategic Context

The Global Carotid Stenotic Scan Devices Market is projected to grow at a CAGR of 6.5%, increasing from USD 1.92 billion in 2025 to USD 2.98 billion by 2032, according to Strategic Market Research. The forecast represents an absolute revenue addition of USD 1.06 billion and market expansion of approximately 55.2% during 2026–2032. Segment shares, revenues, and growth rates included below are based on Strategic Market Research estimates developed from modality utilization, equipment pricing, procedure volumes, installed imaging capacity, and replacement demand.

 

The market covers vascular ultrasound, computed tomography angiography, magnetic resonance angiography, and catheter-based angiography systems used to detect, grade, confirm, and monitor carotid artery narrowing. Duplex and color Doppler ultrasound accounted for an estimated 47.0% share in 2025, equivalent to approximately USD 0.90 billion, making it the largest product segment. CTA represented about 26.0%, MRA approximately 17.0%, and digital-subtraction and catheter angiography nearly 10.0% of global revenue.

 

Commercial demand extends beyond new scanner shipments. Hospitals and diagnostic centers purchase high-frequency linear transducers, Doppler and plaque-visualization software, reporting tools, service agreements, and replacement systems as vascular examination volumes increase. Repeat scans for medically managed patients and follow-up after revascularization create recurring utilization, while acute stroke and TIA work-ups generate episodic demand. Major manufacturers report revenue across broad ultrasound, CT, MRI, and image-guided therapy portfolios, making carotid examination volumes and installed vascular-imaging capacity more useful market indicators than dedicated scanner sales.

 

Disease Burden Supports a Large but Clinically Selected Imaging Pool

An estimated 57.79 million adults aged 30–79 had carotid stenosis of at least 50% globally in 2020. A separate U.S. model estimated approximately 327,721 people with high-grade carotid stenosis. These figures use different disease thresholds and population years, but both indicate a substantial pool requiring risk assessment, medical management, or imaging surveillance. They should not be interpreted as annual scan volumes because many cases remain undiagnosed or do not require frequent imaging.

Stroke and transient ischemic attack broaden the diagnostic pathway. More than 795,000 strokes occur annually in the United States, while approximately 240,000 people experience a TIA each year. Carotid imaging is relevant when clinicians need to determine whether extracranial plaque or stenosis contributed to an ischemic event, but not every stroke or TIA is carotid-related.

Stroke and TIA work-up represented an estimated 24.0% of market revenue in 2025, or approximately USD 0.46 billion. This application is projected to expand at a 6.9% CAGR, reaching nearly USD 0.74 billion by 2032, supported by stronger acute-stroke imaging networks and greater use of vascular imaging in secondary prevention.

Routine screening of the asymptomatic general population does not represent a defensible U.S. growth mechanism. The U.S. Preventive Services Task Force recommends against screening adults without previous stroke or TIA symptoms. Demand is therefore concentrated in clinically indicated evaluation, selected high-risk patients, treatment planning, and surveillance rather than consumer screening programs.

 

Duplex Ultrasound Anchors Recurring Product and Application Demand

Carotid duplex and color Doppler ultrasound form the commercial foundation of the market. The modality is widely used in vascular laboratories, hospitals, outpatient imaging centers, and specialist clinics because it can assess arterial structure and blood-flow characteristics in one examination and can be repeated during follow-up.

The segment generated approximately USD 0.90 billion in 2025, representing 47.0% of global market revenue. It is projected to grow at a 6.0% CAGR and reach nearly USD 1.36 billion by 2032. Its share of total revenue is lower than its share of examination volume because ultrasound systems and individual scans generally carry lower prices than CT, MRI, and interventional angiography procedures.

CMS policy reinforces this first-line position. Medicare’s carotid stenting pathway identifies duplex ultrasound as the initial assessment method, while CTA or MRA provides confirmatory information about stenosis severity, the aortic arch, and extracranial and intracranial circulation. Catheter angiography is generally used when non-invasive results differ materially or when CTA and MRA cannot be performed.

Initial detection and stenosis grading accounted for approximately 31.0% of application revenue in 2025, equivalent to nearly USD 0.60 billion. The segment is expected to grow at about 5.8% CAGR and reach approximately USD 0.88 billion by 2032. Its growth rate remains below the overall market because diagnosis is more episodic than surveillance and procedure-linked imaging.

Recurring surveillance creates a stronger revenue mechanism than diagnosis alone. Medically managed patients may return for progression monitoring, while patients treated with endarterectomy, transfemoral stenting, or TCAR require follow-up for vessel patency and restenosis. Disease progression monitoring accounted for about 15.0% of market revenue in 2025, or USD 0.29 billion, and is projected to reach approximately USD 0.45 billion by 2032 at a 6.6% CAGR.

Portable and compact ultrasound systems expand access in secondary hospitals, outpatient clinics, and decentralized diagnostic services. Premium cart-based equipment remains important in accredited vascular laboratories and tertiary centers where complex plaque assessment, repeatable velocity measurements, and higher examination throughput influence purchasing decisions.

 

CTA, MRA, and Angiography Capture Higher-Value Imaging Episodes

CTA accounted for an estimated 26.0% of the market in 2025, generating approximately USD 0.50 billion. The segment is projected to expand at a 6.7% CAGR and reach nearly USD 0.79 billion by 2032. CTA is well established in acute stroke pathways because it rapidly displays vessel anatomy, calcification, the aortic arch, and intracranial circulation. Its limitations include ionizing radiation and iodinated contrast exposure.

MRA represented approximately 17.0% of global revenue in 2025, equivalent to about USD 0.33 billion. It is expected to record the fastest product-segment CAGR of approximately 7.8%, reaching nearly USD 0.55 billion by 2032. Growth is supported by the expansion of MRI capacity, increasing neurological imaging volumes, and demand for radiation-free vascular assessment.

MRA may be selected when CTA is unsuitable or when neurological MRI is already required. Use can be limited by scan duration, equipment availability, implant compatibility, patient tolerance, and higher operating costs. Hospitals therefore select between CTA and MRA according to urgency, renal function, local protocols, and procedural-planning needs.

Digital-subtraction and catheter angiography accounted for approximately 10.0% of market revenue in 2025, or about USD 0.19 billion. The segment is projected to grow at a 5.8% CAGR and reach nearly USD 0.29 billion by 2032. Its use is narrower because it is invasive and is not generally the first diagnostic examination, but it remains commercially important in complex assessment and carotid stenting.

Large imaging suppliers benefit from selling connected ultrasound, CT, MRI, angiography, and image-management portfolios to stroke centers and vascular programs. The higher capital and procedure value of CTA, MRA, and angiography allows these modalities to generate a substantial share of revenue despite lower examination volumes than ultrasound.

 

Revascularization and Reimbursement Expand Procedure-Linked Imaging

Approximately 45,000 carotid endarterectomies are performed annually in the United States and more than 150,000 worldwide. These procedures create demand for preoperative duplex assessment, confirmatory CTA or MRA, and post-procedure surveillance. They are procedure estimates rather than unique-patient counts, but they demonstrate the scale of the imaging-supported intervention pathway.

Preoperative and pre-stenting assessment accounted for approximately 18.0% of application revenue in 2025, equivalent to nearly USD 0.35 billion. The segment is projected to expand at a 6.4% CAGR and reach approximately USD 0.53 billion by 2032.

TCAR has added another source of recurring imaging demand. Silk Road Medical reported more than 25,000 procedures in 2023, predominantly in the United States, and more than 85,000 cumulative procedures by the end of that year. Boston Scientific completed its approximately USD 1.18 billion acquisition of Silk Road Medical in September 2024, bringing TCAR into a larger peripheral-interventions sales and training network.

Post-revascularization surveillance accounted for an estimated 12.0% of the market in 2025, representing approximately USD 0.23 billion. It is projected to record the fastest application CAGR of about 7.7%, reaching nearly USD 0.39 billion by 2032 as the installed population of patients treated through endarterectomy, transfemoral stenting, and TCAR increases.

CMS broadened national carotid artery stenting coverage effective October 11, 2023 and removed the former requirement for separate CMS facility approval. The policy supports a wider treatment pathway for eligible patients and facilities, indirectly increasing demand for qualifying duplex studies, confirmatory CTA or MRA, procedural angiography, and post-stenting surveillance. It will not translate proportionally into scanner purchases because facilities with sufficient installed capacity can absorb some additional examinations through existing systems.

 

AI and Workflow Software Reshape Purchasing Priorities

Ultrasound quality remains sensitive to operator experience, probe positioning, Doppler-angle selection, and reporting consistency. Vendors are responding with automated measurements, examination protocols, image optimization, plaque-assessment tools, and longitudinal comparison functions.

The near-term commercial opportunity lies in reducing repetitive manual work rather than replacing clinical interpretation. Hospitals are more likely to adopt AI tools when they improve examination consistency, shorten scan or reporting time, and can be deployed through software upgrades. Compatibility with PACS, electronic medical records, and vascular-reporting systems is becoming as important as basic hardware performance.

Hospitals and stroke centers accounted for approximately 48.0% of end-user revenue in 2025, or about USD 0.92 billion, and are projected to reach approximately USD 1.40 billion by 2032 at a 6.2% CAGR. Their leadership reflects access to ultrasound, CT, MRI, angiography, emergency departments, vascular surgery, and stroke programs within the same care environment.

Vascular laboratories represented approximately 18.0% of market revenue in 2025, equal to about USD 0.35 billion, and are expected to grow at a 6.8% CAGR to nearly USD 0.55 billion by 2032. Diagnostic imaging centers accounted for approximately 15.0%, or USD 0.29 billion, and are projected to record the fastest major end-user CAGR of about 7.3%, reaching approximately USD 0.47 billion by 2032.

 

Competitive Landscape

Competition is led by diversified imaging companies rather than carotid-only manufacturers. GE HealthCare, Philips, Siemens Healthineers, Canon Medical Systems, Fujifilm Healthcare, Samsung Medison, and Esaote compete through vascular image quality, Doppler sensitivity, transducer portfolios, software automation, portability, service coverage, and integration with broader stroke-imaging networks.

 

GE HealthCare Builds a Scalable Carotid Imaging Ecosystem Around the LOGIQ Portfolio

GE HealthCare competes through the LOGIQ E10 Series, LOGIQ Fortis, LOGIQ Totus, and portable Vscan Air portfolio. LOGIQ Totus combines multipurpose ultrasound with AI-supported workflow and decision support, while GE’s broader strategy emphasizes software upgrades and an open application environment. For carotid imaging, the company’s position rests on color and spectral Doppler performance, vascular presets, linear transducers, and the ability to standardize systems across hospital departments.

 

Philips Advances Flow Visualization and Software-Led Ultrasound Upgrades

Philips addresses premium and high-throughput imaging through EPIQ Elite, Affiniti, and compact ultrasound systems. Its Elevate software release added AI-assisted workflow and quantitative measurement capabilities, while the 2026 Elevate Plus clearance extended automation across EPIQ Elite and Affiniti. Philips competes in carotid care through Doppler imaging, flow visualization, transducer compatibility, remote upgrades, and common interfaces across several system tiers.

 

Siemens Healthineers Targets Consistent Carotid Measurements With ACUSON Sequoia

Siemens Healthineers competes through ACUSON Sequoia and its wider CT, MRI, angiography, and digital-imaging portfolio. The December 2024 ACUSON Sequoia 3.5 update added AI-supported recognition, automated measurements, and workflow improvements. The emphasis on standardization and reduced operator variation is relevant to vascular laboratories performing repeat stenosis measurements.

 

Canon Medical Connects Ultrasound, CTA, MRA, and Angiography Across the Carotid Pathway

Canon Medical participates across ultrasound, CTA, MRA, and angiography through its Aplio, Aquilion, Vantage, and Alphenix families. Aplio systems support vascular imaging and automated measurement functions, while Canon’s wider portfolio allows hospitals to source several stages of the carotid pathway from one supplier.

 

Fujifilm Healthcare Strengthens Low-Flow Imaging With ARIETTA DeepInsight

Fujifilm competes through the ARIETTA portfolio. In February 2026, it introduced the ARIETTA DeepInsight x range, combining deep-learning-based image processing, automatic focusing, workflow recognition, and Detective Flow Imaging for low-velocity blood-flow visualization.

 

Samsung Medison Brings AI-Assisted Vascular Imaging Into the Premium Ultrasound Segment

Samsung Medison introduced the premium R20 ultrasound system at RSNA 2025 with a new imaging engine, software beamforming, AI-supported tools, and automated measurements. Its broader V-series portfolio includes flow-visualization and arterial-analysis capabilities on selected configurations.

 

Esaote Targets Decentralized Vascular Imaging With Compact MyLab Systems

Esaote competes through systems such as MyLab E80, MyLab A70, MyLab A50, and MyLab Omega. The MyLab E80, introduced in June 2024, added configurable workflows, multiple probe connectors, battery-supported operation, and tools for complex imaging.

 

Carotid Competition Depends on Vascular Capability, Not Company-Wide Ultrasound Revenue

Carotid-specific company market shares should not be calculated from total ultrasound revenue because each vendor has different exposure to cardiology, women’s health, abdominal imaging, point-of-care ultrasound, and other applications.

 

Regional Market Outlook

North America

North America held approximately 38.0% of the global market in 2025, representing nearly USD 0.73 billion. The regional market is projected to grow at about 5.9% CAGR and reach approximately USD 1.09 billion by 2032, according to Strategic Market Research estimates.

Demand is supported by mature hospital imaging networks, Medicare coverage, accredited vascular laboratories, outpatient imaging centers, and substantial carotid intervention activity. Growth will come primarily from replacement systems, software upgrades, procedure-linked imaging, and surveillance rather than population screening.

 

Europe

Europe accounted for approximately 29.0% of global revenue in 2025, or about USD 0.56 billion. The market is expected to expand at roughly 5.7% CAGR and reach nearly USD 0.82 billion by 2032, according to Strategic Market Research estimates.

Public procurement, replacement of aging equipment, pressure to reduce invasive angiography, and demand for standardized reporting shape the regional market. Automated measurements and workflow tools are becoming more relevant as vascular departments manage workforce and examination-capacity pressures.

 

Asia-Pacific

Asia-Pacific represented approximately 23.0% of the market in 2025, equivalent to nearly USD 0.44 billion. It is projected to record the fastest CAGR of about 8.2%, reaching approximately USD 0.77 billion by 2032 and increasing its global share to around 25.8%, according to Strategic Market Research estimates.

Population size, stroke burden, private healthcare investment, and expansion of diagnostic capacity support regional growth. Ultrasound is particularly suited to secondary hospitals and diagnostic centers because it requires less capital and infrastructure than CT or MRI.

 

Latin America, the Middle East, and Africa

Latin America, the Middle East, and Africa collectively accounted for approximately 10.0% of the market in 2025, generating nearly USD 0.19 billion. The combined market is forecast to grow at about 6.8% CAGR and reach approximately USD 0.30 billion by 2032, according to Strategic Market Research estimates.

Demand is linked to private hospital development, stroke-service expansion, and modernization of imaging infrastructure. Ultrasound will remain the most accessible carotid-imaging product in areas with limited CT, MRI, or angiography capacity.

 

Market Outlook

The market will expand as stroke services, vascular laboratories, and intervention programs invest in higher examination capacity and more consistent reporting. Duplex ultrasound will remain the largest product segment, increasing from approximately USD 0.90 billion in 2025 to USD 1.36 billion by 2032, while MRA is expected to record the fastest product CAGR at about 7.8%.

Hospitals and stroke centers will remain the largest end-user segment with an estimated 48.0% share in 2025, while diagnostic imaging centers are projected to record faster growth at approximately 7.3% CAGR. Post-revascularization surveillance will be the fastest-growing application at about 7.7% CAGR, supported by the expanding population of patients requiring follow-up after endarterectomy, carotid stenting, and TCAR.

The strongest revenue opportunities will arise from replacement systems, vascular transducers, software upgrades, automated measurements, maintenance contracts, reporting platforms, and longitudinal surveillance. Vendors that connect ultrasound with cross-sectional imaging, angiography, structured reporting, and follow-up workflows will be better positioned than suppliers competing only on scanner specifications.

 

Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 1.92 Billion
Revenue Forecast in 2032	USD 2.98 Billion
Overall Growth Rate	CAGR of 6.5% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
Segmentation	By Product, By Application, By End User, By Geography
By Product	Carotid Duplex and Color Doppler Ultrasound Systems, Computed Tomography Angiography Systems, Magnetic Resonance Angiography Systems, Digital-Subtraction and Catheter Angiography Systems
By Application	Initial Detection and Stenosis Grading, Stroke and Transient Ischemic Attack Work-Up, Preoperative and Pre-Stenting Assessment, Disease Progression Monitoring, Post-Revascularization Surveillance
By End User	Hospitals and Stroke Centers, Vascular Laboratories, Diagnostic Imaging Centers, Vascular Surgery and Specialist Clinics, Ambulatory and Interventional Centers, Academic and Research Institutions
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Country Scope	United States, Canada, Mexico, Germany, United Kingdom, France, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Brazil, Argentina, Saudi Arabia, United Arab Emirates, South Africa
Market Drivers	Rising clinical focus on early carotid stenosis detection and stroke-risk assessment; growing use of non-invasive duplex ultrasound for screening and routine monitoring; increasing demand for CTA and MRA in treatment planning; expanding post-stenting and post-endarterectomy surveillance requirements
Customization Option	Available upon request